Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan Sells 9,568 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Gilla Kaplan sold 9,568 shares of the stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $9.78, for a total transaction of $93,575.04. Following the completion of the sale, the director now directly owns 28,231 shares of the company's stock, valued at approximately $276,099.18. This trade represents a 25.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Gilla Kaplan also recently made the following trade(s):

• On Tuesday, June 17th, Gilla Kaplan sold 10 shares of Tyra Biosciences stock. The stock was sold at an average price of $10.35, for a total value of $103.50.
• On Monday, June 16th, Gilla Kaplan sold 6,814 shares of Tyra Biosciences stock. The shares were sold at an average price of $10.38, for a total value of $70,729.32.
• On Friday, June 13th, Gilla Kaplan sold 15,000 shares of Tyra Biosciences stock. The stock was sold at an average price of $10.31, for a total value of $154,650.00.
• On Thursday, June 12th, Gilla Kaplan sold 30,000 shares of Tyra Biosciences stock. The shares were sold at an average price of $10.31, for a total value of $309,300.00.

Tyra Biosciences Stock Up 5.2%

Tyra Biosciences stock traded up $0.48 during mid-day trading on Monday, hitting $9.71. 323,374 shares of the company were exchanged, compared to its average volume of 281,520. Tyra Biosciences, Inc. has a 1-year low of $6.42 and a 1-year high of $29.60. The business has a fifty day moving average of $9.76 and a 200 day moving average of $11.72. The company has a market capitalization of $515.50 million, a PE ratio of -5.96 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. Research analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TYRA shares. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, March 31st. Piper Sandler assumed coverage on shares of Tyra Biosciences in a report on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price objective for the company. Finally, Wedbush reiterated an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, March 28th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $30.83.

Institutional Trading of Tyra Biosciences

Several hedge funds have recently modified their holdings of TYRA. Rhumbline Advisers grew its position in Tyra Biosciences by 7.2% during the 1st quarter. Rhumbline Advisers now owns 28,081 shares of the company's stock worth $261,000 after acquiring an additional 1,879 shares during the last quarter. Jane Street Group LLC acquired a new position in Tyra Biosciences in the first quarter worth $324,000. Woodline Partners LP bought a new stake in shares of Tyra Biosciences during the first quarter worth $931,000. Goldman Sachs Group Inc. increased its stake in shares of Tyra Biosciences by 21.7% in the first quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company's stock valued at $725,000 after buying an additional 13,896 shares in the last quarter. Finally, Polar Asset Management Partners Inc. raised its holdings in shares of Tyra Biosciences by 27.1% in the first quarter. Polar Asset Management Partners Inc. now owns 141,241 shares of the company's stock valued at $1,314,000 after buying an additional 30,134 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company's stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.